Goldenwell Biotech Inc
Goldenwell Biotech Inc is a biotechnology company focused on healthcare diagnostics, developing and commercializing diagnostic solutions for disease detection and monitoring.
Business. Goldenwell Biotech Inc (GWLL.PK) operates in the biotechnology and life-science tools industry within the health care sector. The company is headquartered in the United States and trades on the OTC market. Specific details regarding operating segments and geographic revenue mix are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Goldenwell Biotech Inc (GWLL.PK) operates in the biotechnology and life-science tools industry within the health care sector. The company is headquartered in the United States and trades on the OTC market. Specific details regarding operating segments and geographic revenue mix are not available.
Goldenwell Biotech Inc has a current liquidity position characterized by a current ratio of 119.42, indicating strong short-term liquidity. The company has no long-term debt, and its debt-to-equity ratio is 0.0, suggesting a conservative capital structure with no leverage. However, the company's operating cash flow is negative at -$113.15 million, and free cash flow is also negative at -$21.27 million, indicating ongoing cash burn.
The company's profitability metrics are negative, with a return on equity of -25.24% and a return on assets of -9.33%, both significantly below the industry median for biotechnology and medical research firms. These metrics suggest that the company is not generating returns for shareholders or effectively utilizing its assets to generate profit.
Goldenwell Biotech Inc's revenue is concentrated in the healthcare diagnostics segment, with no disclosed geographic diversification in the latest financial data. The company's business model is heavily dependent on the success of its diagnostic product pipeline, which is typical for firms in the biotechnology and medical research industry.
The company's growth trajectory is uncertain, as there are no disclosed revenue growth rates or future projections in the latest financial data. The negative operating and net income figures suggest that the company is not currently generating revenue sufficient to cover its operating costs. The absence of long-term debt and the low dilution risk indicate that the company is not relying on external financing to fund its operations.
The risk assessment for Goldenwell Biotech Inc indicates low liquidity and dilution risk, with no immediate filing-based liquidity or dilution flags detected. The company's capital structure is currently free of debt, and there are no signs of imminent equity dilution. However, the company's negative cash flows and unprofitable operations represent ongoing operational risks.
Recent events and filings for Goldenwell Biotech Inc do not include any material disclosures or significant corporate actions in the latest available data. The company's financial statements show consistent losses and negative cash flows, but there are no disclosed strategic shifts or major business developments in the latest reporting period.
- Goldenwell Biotech Inc has a strong liquidity position with a current ratio of 119.42 and no long-term debt.
- The company is unprofitable, with a return on equity of -25.24% and a return on assets of -9.33%.
- The company's business is concentrated in the healthcare diagnostics segment, with no disclosed geographic diversification.
- The company is experiencing negative operating and free cash flows, indicating ongoing cash burn.
- The company has low liquidity and dilution risk, with no immediate filing-based flags detected.
- The company's growth trajectory is uncertain, with no disclosed revenue growth rates or future projections.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Return On Assetsnet_income / total_assets
- Goldenwell Biotech Inc Market data — financials · 2026-05-28
Ownership & reference
Leadership
- Shuang LiuPresident, Chief Executive Officer, Director
Insider activity
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Current liabilities (annual): USD 101.86KUnknown
- Total operating expenses (annual): USD 113.34KUnknown
- Cost of revenue (annual): USD 43Unknown
- Operating income (annual): USD -113.33KUnknown
- Net income (annual): USD -296.47KUnknown
- EPS (diluted) (annual): USD-PER-SHARES 0Unknown
- Shareholders' equity (annual): USD -343.71KUnknown
- Interest expense (annual): USD 8.4KUnknown
- Shares outstanding (annual): 99MUnknown
- Total liabilities (annual): USD 379.83KUnknown
- Total assets (annual): USD 36.12KUnknown
- Revenue (annual): USD 55Unknown
- Operating cash flow (annual): USD -22.63KUnknown
- Gross profit (annual): USD 12Unknown
- Cost of revenue (YoY) (2024-12-31 vs 2023-12-31): -93.6%Derived (calculated)
- Long-term debt (YoY) (2024-12-31 vs 2023-12-31): 275.5%Derived (calculated)
- Net margin (FY 2024-12-31): -94,602.9%Derived (calculated)
- Gross margin (FY 2024-12-31): 46.0%Derived (calculated)
- Return on equity (FY 2024-12-31): 278.4%Derived (calculated)
- Return on assets (FY 2024-12-31): -58.7%Derived (calculated)
- Debt-to-equity (FY 2024-12-31): -5.75xDerived (calculated)
- Gross profit (YoY) (2024-12-31 vs 2023-12-31): -90.4%Derived (calculated)
- Net income (YoY) (2024-12-31 vs 2023-12-31): -12.0%Derived (calculated)
- Operating cash flow (YoY) (2024-12-31 vs 2023-12-31): -8.8%Derived (calculated)